Kelani K, Hegazy M, Hassan A, Tantawy M
RSC Adv. 2022; 11(12):7051-7058.
PMID: 35423192
PMC: 8694919.
DOI: 10.1039/d0ra10598h.
Salimi M, Ghazvineh S, Zare M, Parsazadegan T, Dehdar K, Nazari M
PLoS One. 2019; 14(9):e0221978.
PMID: 31509547
PMC: 6738655.
DOI: 10.1371/journal.pone.0221978.
Frati F, DellAlbani I, Passalacqua G, Bonini S, Rossi O, Senna G
Med Sci Monit. 2014; 20:2151-6.
PMID: 25366169
PMC: 4228947.
DOI: 10.12659/MSM.891206.
Almaliotis D, Michailopoulos P, Gioulekas D, Giouleka P, Papakosta D, Siempis T
World Allergy Organ J. 2013; 6(1):12.
PMID: 23866689
PMC: 3726364.
DOI: 10.1186/1939-4551-6-12.
Wijk R
Mediators Inflamm. 1995; 4(7):S31-8.
PMID: 18475688
PMC: 2365679.
DOI: 10.1155/S0962935195000822.
Onset and duration of action of ketotifen 0.025% and emedastine 0.05% in seasonal allergic conjunctivitis : efficacy after repeated pollen challenges in the vienna challenge chamber.
Horak F, Stubner P, Zieglmayer R, Kawina A, Moser M, Lanz R
Clin Drug Investig. 2007; 23(5):329-37.
PMID: 17535045
DOI: 10.2165/00044011-200323050-00003.
Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis.
Kidd M, McKenzie S, Steven I, Cooper C, Lanz R
Br J Ophthalmol. 2003; 87(10):1206-11.
PMID: 14507747
PMC: 1920791.
DOI: 10.1136/bjo.87.10.1206.
Allergic ocular disease. A review of pathophysiology and clinical presentations.
Bielory L, Goodman P, Fisher E
Clin Rev Allergy Immunol. 2001; 20(2):183-200.
PMID: 11349609
DOI: 10.1385/CRIAI:20:2:183.
Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries.
Pinto C, Lafuma A, Fagnani F, Nuijten M, Berdeaux G
Pharmacoeconomics. 2001; 19(3):255-65.
PMID: 11303414
DOI: 10.2165/00019053-200119030-00004.
Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.
Schadlich P, Brecht J
Pharmacoeconomics. 2000; 17(1):37-52.
PMID: 10747764
DOI: 10.2165/00019053-200017010-00003.
Economic outcomes for the treatment of allergic rhinitis.
Kozma C, SADIK M, Watrous M
Pharmacoeconomics. 1996; 10(1):4-13.
PMID: 10172730
DOI: 10.2165/00019053-199610010-00002.
Allergic eye disease mechanisms.
McGill J, Holgate S, Church M, Anderson D, Bacon A
Br J Ophthalmol. 1999; 82(10):1203-14.
PMID: 9924312
PMC: 1722368.
DOI: 10.1136/bjo.82.10.1203.
The role of oak pollen in hay fever consultations in general practice and the factors influencing patients' decisions to consult.
Ross A, Corden J, Fleming D
Br J Gen Pract. 1996; 46(409):451-5.
PMID: 8949322
PMC: 1239713.
The pharmacokinetic properties of topical levocabastine. A review.
Heykants J, Van Peer A, Van De Velde V, Snoeck E, Meuldermans W, Woestenborghs R
Clin Pharmacokinet. 1995; 29(4):221-30.
PMID: 8549024
DOI: 10.2165/00003088-199529040-00002.
Labelling of rhinitis and hayfever by doctors.
Sibbald B, Rink E
Thorax. 1991; 46(5):378-81.
PMID: 2068696
PMC: 1020970.
DOI: 10.1136/thx.46.5.378.
Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history.
Sibbald B, Rink E
Thorax. 1991; 46(12):895-901.
PMID: 1792637
PMC: 463495.
DOI: 10.1136/thx.46.12.895.
Drug treatment of allergic conjunctivitis. A review of the evidence.
Ciprandi G, BUSCAGLIA S, Cerqueti P, Canonica G
Drugs. 1992; 43(2):154-76.
PMID: 1372215
DOI: 10.2165/00003495-199243020-00003.
